The Centers for Medicare and Medicaid Services said this week it’s opening a National Coverage Determination analysis, a process that will allow the agency to review and determine whether Medicare will establish a national coverage policy for monoclonal antibodies targeting amyloid for the treatment of Alzheimer’s disease.
CMS opens national coverage determination analysis on Alzheimer’s treatment
